Yervoy Pregnancy Surveillance Study

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Melanoma

Treatments: Drug: Yervoy

Study type: Observational

Funder types: Industry

Identifiers

NCT02854488

CA184-487

Details and patient eligibility

About

The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment

Exclusion criteria

• Women whose ipilimumab exposure is outside the window of pregnancy exposure
• Pregnancies for which there is only paternal exposure to Yervoy

Other protocol defined inclusion/exclusion criteria could apply

Trial design

0 participants in 1 patient group

Women Exposed to Yervoy (ipilimumab) During Pregnancy

Description:

Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies

Treatment:

Drug: Yervoy